These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 28009472)
1. Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study. Forst T; Falk A; Andersen G; Fischer A; Weber MM; Voswinkel S; Heise T; Kapitza C; Plum-Mörschel L Diabetes Obes Metab; 2017 Apr; 19(4):489-495. PubMed ID: 28009472 [TBL] [Abstract][Full Text] [Related]
2. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment. Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063 [TBL] [Abstract][Full Text] [Related]
3. Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study. Forst T; Alghdban MK; Fischer A; Weber MM; Voswinkel S; Heise T; Kapitza C; Plum-Mörschel L Horm Metab Res; 2018 May; 50(5):403-407. PubMed ID: 29727906 [TBL] [Abstract][Full Text] [Related]
4. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus. Jain RK Expert Opin Pharmacother; 2017 Apr; 18(6):545-549. PubMed ID: 28375658 [TBL] [Abstract][Full Text] [Related]
5. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes. Tan X; Hu J Ann Endocrinol (Paris); 2016 Oct; 77(5):557-562. PubMed ID: 27062036 [TBL] [Abstract][Full Text] [Related]
6. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function. Alba M; Ahrén B; Inzucchi SE; Guan Y; Mallick M; Xu L; O'Neill EA; Williams-Herman DE; Kaufman KD; Goldstein BJ Diabetes Obes Metab; 2013 Dec; 15(12):1101-10. PubMed ID: 23782502 [TBL] [Abstract][Full Text] [Related]
7. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial. Kawamori R; Haneda M; Suzaki K; Cheng G; Shiki K; Miyamoto Y; Solimando F; Lee C; Lee J; George J Diabetes Obes Metab; 2018 Sep; 20(9):2200-2209. PubMed ID: 29766636 [TBL] [Abstract][Full Text] [Related]
8. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes. Kim ES; Deeks ED Drugs; 2015 Sep; 75(13):1547-57. PubMed ID: 26323340 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes. Rizos CV; Filippatos TD; Elisaf MS Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374 [TBL] [Abstract][Full Text] [Related]
10. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910 [TBL] [Abstract][Full Text] [Related]
11. A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes. Gallwitz B Expert Opin Drug Saf; 2017 Dec; 16(12):1399-1405. PubMed ID: 28934557 [TBL] [Abstract][Full Text] [Related]
12. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. Aronson R Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379 [TBL] [Abstract][Full Text] [Related]
13. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Kern M; Klöting N; Mark M; Mayoux E; Klein T; Blüher M Metabolism; 2016 Feb; 65(2):114-23. PubMed ID: 26773934 [TBL] [Abstract][Full Text] [Related]
14. Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials. DeFronzo RA; Lee C; Kohler S Adv Ther; 2018 Jul; 35(7):1009-1022. PubMed ID: 29949041 [TBL] [Abstract][Full Text] [Related]
15. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. Lingvay I; Beetz N; Sennewald R; Schuler-Metz A; Bertulis J; Loley C; Lang B; Lippert C; Lee J; Manning LS; Terada D Postgrad Med; 2020 May; 132(4):337-345. PubMed ID: 32366156 [TBL] [Abstract][Full Text] [Related]
16. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial. Søfteland E; Meier JJ; Vangen B; Toorawa R; Maldonado-Lutomirsky M; Broedl UC Diabetes Care; 2017 Feb; 40(2):201-209. PubMed ID: 27913576 [TBL] [Abstract][Full Text] [Related]
17. Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial. Kaku K; Haneda M; Tanaka Y; Lee G; Shiki K; Miyamoto Y; Solimando F; Lee J; Lee C; George J Diabetes Obes Metab; 2019 Jan; 21(1):136-145. PubMed ID: 30091172 [TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials. Watada H; Yamauchi T; Yamamoto F; Taniguchi A; Yarush L; Heilmann C; Yasui A Expert Opin Drug Saf; 2020 Sep; 19(9):1193-1202. PubMed ID: 32552153 [TBL] [Abstract][Full Text] [Related]
19. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K; Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850 [TBL] [Abstract][Full Text] [Related]
20. Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. Al Jobori H; Daniele G; Adams J; Cersosimo E; Triplitt C; DeFronzo RA; Abdul-Ghani M Diabetes Obes Metab; 2017 Jun; 19(6):809-813. PubMed ID: 28128510 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]